Annovis Bio to Present at Benzinga Global Small Cap Conference on December 8, 2020
December 07 2020 - 4:05PM
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug
platform company addressing Alzheimer’s disease (AD), Parkinson’s
disease (PD) and other neurodegenerative diseases, today announced
its CEO, Maria Maccecchini, Ph.D., will present at Benzinga's
inaugural Global SmallCap Conference on Tuesday, December 8, 2020
at 4:30 pm ET.
Investors interested in viewing Annovis Bio's
presentation may register with free access here for the
two-day conference which takes place virtually from December 8-9,
2020.
During the presentation, Dr. Maccecchini will
discuss the Company’s unique approach to AD and other
neurodegenerative diseases, current pipeline, and upcoming
milestones, including expected publication of data from its current
Phase 2a studies in AD and PD.
About
Benzinga
Benzinga is a leading financial media company
dedicated to making information easier to consume. Benzinga's news
desk is constantly breaking stories and moving billions of dollars
of market capitalization through its real-time news tool, Benzinga
Pro. Benzinga's original content is syndicated to 70 partner
websites including Yahoo! Finance MSN, CNNMoney, Fox Business and
MarketWatch.
About Annovis
Bio
Headquartered in Berwyn, Pennsylvania, Annovis
Bio, Inc. (Annovis) is a clinical-stage, drug platform company
addressing neurodegeneration, such as Alzheimer’s disease (AD),
Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
We believe that we are the only company developing a drug for AD,
PD and AD-DS that inhibits more than one neurotoxic protein and,
thereby, improves the information highway of the nerve cell, known
as axonal transport. When this information flow is impaired, the
nerve cell gets sick and dies. We expect our treatment to improve
memory loss and dementia associated with AD and AD-DS, as well as
body and brain function in PD. We have an ongoing Phase 2a study in
AD patients and have commenced a second Phase 2a study in AD and PD
patients. For more information on Annovis, please visit the
company’s website: www.annovisbio.com.
Investor Relations:
Dave Gentry, CEORedChip Companies
Inc.407-491-4498Dave@redchip.com
SOURCE: Annovis Bio, Inc.
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Apr 2023 to Apr 2024